3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
3
Myelodysplastic Syndromes
2
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Epidermolysis Bullosa Dystrophica
1
Cytopenia
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anemia, Refractory
1
Adenocarcinoma
1
Interventions
pembrolizumab
8
Cetuximab
8
Cisplatin
6
Fluorouracil
5
Paclitaxel
4
durvalumab
3
Radiotherapy
3
Leucovorin
3
Docetaxel
3
Carboplatin
3
tremelimumab
2
niraparib
2
avelumab
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Nivolumab
2
Ipilimumab
2
Bevacizumab
2
zalutumumab
1
yeast-CEA vaccine
1
spartalizumab
1
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
regorafenib
1
penpulimab
1
paclitaxel poliglumex
1
osimertinib
1
necitumumab
1
dostarlimab
1
demplatin pegraglumer
1
cobimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Squamous Cell
×
ON 01910
×
Clear all
NCT03786237
2026-02-24
Rigosertib for RDEB-SCC
Salzburger Landeskliniken
Phase 1/2
Completed
2 enrolled